Cargando…

Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma

Peripheral T-cell lymphoma (PTCL) is a rare, heterogenous malignancy with dismal outcomes at relapse. Hypomethylating agents (HMA) have an emerging role in PTCL, supported by shared mutations with myelodysplasia (MDS). Response rates to azacitidine in PTCL of follicular helper cell origin are promis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Jonathan, Gruber, Emily, Maher, Belinda, Waltham, Mark, Sabouri-Thompson, Zahra, Jong, Ian, Luong, Quinton, Levy, Sidney, Kumar, Beena, Brasacchio, Daniella, Jia, Wendy, So, Joan, Skinner, Hugh, Lewis, Alexander, Hogg, Simon J., Vervoort, Stephin, DiCorleto, Carmen, Uhe, Micheleine, Gamgee, Jeanette, Opat, Stephen, Gregory, Gareth P., Polekhina, Galina, Reynolds, John, Hawkes, Eliza A., Kailainathan, Gajan, Gasiorowski, Robin, Kats, Lev M., Shortt, Jake
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162925/ https://www.ncbi.nlm.nih.gov/pubmed/35459873 http://dx.doi.org/10.1038/s41375-022-01571-8

Ejemplares similares

Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI‐110) in Myeloid Malignancies
por: Xu, Cong, et al.
Publicado: (2017)

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
por: Papadatos-Pastos, Dionysis, et al.
Publicado: (2022)

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma
por: Jueliger, Simone, et al.
Publicado: (2016)

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
por: Tatarczuch, Maciej, et al.
Publicado: (2023)

P1261: ALLG LABORATORY SCIENCE STUDY LS21: MOLECULAR CORRELATES OF RESPONSE IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (RRMZL) PATIENTS TREATED WITH ZANUBRUTINIB IN THE MAGNOLIA TRIAL
por: Tatarczuch, M., et al.
Publicado: (2022)

Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma
por: Costacurta, Matteo, et al.
Publicado: (2020)

Two New SGI1-LK Variants Found in Proteus mirabilis and Evolution of the SGI1-HKL Group of Salmonella Genomic Islands
por: de Curraize, Claire, et al.
Publicado: (2020)

3rd European Cray/SGI MPP Workshop
Publicado: (1997)

5th European SGI-Cray MPP Workshop
Publicado: (1999)

SGI: automatic clinical subgroup identification in omics datasets
por: Buyukozkan, Mustafa, et al.
Publicado: (2021)

P075: My Hodgkin, My Health: Feasibility of a mobile application to collect long term follow up data about Hodgkin patients
por: Kailainathan, Gajan, et al.
Publicado: (2022)

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2017)

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
por: Chung, Woonbok, et al.
Publicado: (2019)

Mass balance and metabolite profiling of (14)C-guadecitabine in patients with advanced cancer
por: Roosendaal, Jeroen, et al.
Publicado: (2019)

Molecular mechanisms of Guadecitabine induced FGFR4 down regulation in alveolar rhabdomyosarcomas
por: Darvishi, Emad, et al.
Publicado: (2020)

Erratum for de Curraize et al., “Two New SGI1-LK Variants Found in Proteus mirabilis and Evolution of the SGI1-HKL Group of Salmonella Genomic Islands”
por: de Curraize, Claire, et al.
Publicado: (2020)

A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer
por: Albany, Costantine, et al.
Publicado: (2020)

Intra-arterial adenoviral mediated tumor transfection in a novel model of cancer gene therapy
por: Cabrera, Gustavo, et al.
Publicado: (2006)

PRMT5-Mediated Methylation of NF-κB p65 at Arg(174) Is Required for Endothelial CXCL11 Gene Induction in Response to TNF-α and IFN-γ Costimulation
por: Harris, Daniel P., et al.
Publicado: (2016)

Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine
por: Albany, Costantine, et al.
Publicado: (2016)

DNA Methyltransferase 1 Targeting Using Guadecitabine Inhibits Prostate Cancer Growth by an Apoptosis-Independent Pathway
por: Karan, Dev, et al.
Publicado: (2023)

Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS
por: Gregory, Gareth P., et al.
Publicado: (2019)

Immunomodulatory activity of SGI-110: a basis for novel chemo-immunotherapeutic combinations in cancer treatment
por: Covre, Alessia, et al.
Publicado: (2013)

Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts
por: Srivastava, Pragya, et al.
Publicado: (2015)

“Does the Salmonella Genomic Island 1 (SGI1) confer invasiveness properties to human isolates?”
por: de Curraize, Claire, et al.
Publicado: (2017)

DNMTs inhibitor SGI-1027 induces apoptosis in Huh7 human hepatocellular carcinoma cells
por: Sun, Ning, et al.
Publicado: (2018)

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study
por: Fenaux, Pierre, et al.
Publicado: (2023)

Identification and Characterization of New Resistance-Conferring SGI1s (Salmonella Genomic Island 1) in Proteus mirabilis
por: Bie, Luyao, et al.
Publicado: (2018)

SGI-4 in Monophasic Salmonella Typhimurium ST34 Is a Novel ICE That Enhances Resistance to Copper
por: Branchu, Priscilla, et al.
Publicado: (2019)

A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
por: Jang, H. Josh, et al.
Publicado: (2023)

Detection of SGI1/PGI1 Elements and Resistance to Extended-Spectrum Cephalosporins in Proteae of Animal Origin in France
por: Schultz, Eliette, et al.
Publicado: (2017)

Preclinical characterization of the JAK/STAT inhibitor SGI-1252 on skeletal muscle function, morphology, and satellite cell content
por: Sorensen, Jacob R., et al.
Publicado: (2018)

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
por: Sébert, Marie, et al.
Publicado: (2019)

Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer
por: Hogg, Simon J., et al.
Publicado: (2022)

Molecular Modeling Studies of the Novel Inhibitors of DNA Methyltransferases SGI-1027 and CBC12: Implications for the Mechanism of Inhibition of DNMTs
por: Yoo, Jakyung, et al.
Publicado: (2013)

DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma
por: Li, Juan, et al.
Publicado: (2022)

P1678: INTERVENTIONS AND THERAPY AT END OF LIFE IN HAEMATOLOGICAL MALIGNANCY: A RETROSPECTIVE COHORT STUDY ON HEALTHCARE UTILISATION
por: Shaw, Briony, et al.
Publicado: (2023)

P1212: RATIONALLY DESIGNED CHIMERIC PI3K-BET BROMODOMAIN INHIBITORS ELICIT CURATIVE RESPONSES IN MYC-DRIVEN LYMPHOMA
por: Oh, Danielle H., et al.
Publicado: (2023)

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias
por: Kim, Sang-Kyu, et al.
Publicado: (2018)

Salmonella genomic island 1 (SGI1) reshapes the mating apparatus of IncC conjugative plasmids to promote self-propagation
por: Carraro, Nicolas, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_frb18plu3nurrke8hv3iv1771c